News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Pharmaceuticals, Inc. Release: Dabigatran Etexilate as Effective and Safe as Enoxaparin in Preventing Venous Thromboembolism (VTE) After Total Hip Replacement Surgery and Significantly Reduced the Combined Endpoint of Major VTE and VTE-Related Death



6/11/2010 11:50:13 AM

INGELHEIM, Germany--(BUSINESS WIRE)--For NON-US Healthcare Media Only

Data from the RE-NOVATE® II study presented today at the 15th Annual Congress of the European Hematology Association (EHA) have shown that dabigatran etexilate 220mg once daily is as effective and safe as enoxaparin 40mg in preventing venous thromboembolism (VTE) after total hip replacement surgery. The results also showed that dabigatran etexilate significantly reduced the combined endpoint of major VTE and VTE-related death compared to enoxaparin.1


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES